Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,231 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease COPD Clear all
Terminated No phase listed Observational Results available

Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma

NCT02487394
View directory record Official record
Conditions
Asthma, COPD
Interventions
Exhaled Breath Condensate (EBC)
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

NCT03265145
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Stiolto Respimat, ICS (Inhaled Corticosteroid) (Triple therapy), LABA (Long-Acting Beta Agonist) (Triple therapy), LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
90
States / cities
Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Adjusting to Chronic Conditions Using Education, Support, and Skills

NCT01149772
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Heart Failure, Anxiety, Depression
Interventions
ACCESS
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Oct 6, 2026, 10:13 PM EDT
Recruiting No phase listed Observational

PiMZ Longitudinal Cohort (PiMZ Logic)

NCT06505603
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema or COPD
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 2 Interventional

Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease

NCT00672802
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
Ramelteon and Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
6
States / cities
Birmingham, Alabama • Santa Monica, California • Miami Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478683
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 6, 2026, 10:13 PM EDT
Not listed Not applicable Interventional Results available

Gala Early Feasibility Study of RheOx

NCT03631472
View directory record Official record
Conditions
Chronic Bronchitis, Copd Bronchitis
Interventions
RheOx
Device
Lead sponsor
Gala Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Jacksonville, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

COPD E-cigarette Topography Training

NCT05510154
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Tobacco Smoking
Interventions
Brief advice, Single Training, Training to Competency
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers

NCT02098369
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Written education material (basic), Additional education material, PELICAN-Proactive, PELICAN-Reactive
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Lake Forest, California • Torrance, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 6, 2026, 10:13 PM EDT
Not yet recruiting Phase 2 Interventional

GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD

NCT07747805
View directory record Official record
Conditions
COPD, Obesity & Overweight, Sarcopenia
Interventions
Tirzepatide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Oral Supplement and Acute Resistance Exercise

NCT06801951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
acute resistance exercise with oral nutrition supplementation, stable tracer infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 6, 2026, 10:13 PM EDT
Completed No phase listed Observational Results available

Reveal LINQ for Chronic Obstructive Pulmonary Disease (COPD)

NCT04169529
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Reveal LINQ
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
45 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Brandon, Florida • Jacksonville, Florida • Leesburg, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Stabilization of Hypercapnia: NIPPV v HVNI

NCT04709562
View directory record Official record
Conditions
Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease, Dyspnea, Hypercapnic Acidosis
Interventions
High Velocity Nasal Insufflation (HVNI), Noninvasive Positive Pressure Ventilation (NIPPV)
Device
Lead sponsor
Vapotherm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Oxnard, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Results available

Actuation Indicator Trial in Patients With COPD

NCT00928746
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Ipratropium bromide
Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
7
States / cities
Lafayette, Louisiana • Easley, South Carolina • Gaffney, South Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 2 Interventional

Efficacy of Osteopathic Manipulation in Chronic Obstructive Pulmonary Disease

NCT00034112
View directory record Official record
Conditions
Emphysema
Interventions
osteopathic manipulative treatment
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Results available

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

NCT02130193
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 6, 2026, 10:13 PM EDT
Withdrawn Not applicable Interventional

Breath Actuated Nebulizer Study Protocol

NCT00382447
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease
Interventions
standard nebulizer, breath actuated nebulizer
Device
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 6, 2026, 10:13 PM EDT
Completed No phase listed Observational

Assessment of Pulmonary Specialty Physicians' Approach to Advanced Care Planning in Patients With Chronic Pulmonary Diseases

NCT01825538
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
Jennifer McCallister MD
Other
Eligibility
18 Years to 88 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Oct 6, 2026, 10:13 PM EDT
Recruiting Phase 2 Interventional

The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)

NCT05237505
View directory record Official record
Conditions
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Overlap Syndrome
Interventions
bi-level positive pressure non invasive ventilation, Oxygen gas
Device · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 1 Interventional

Bronchoscopic Thermal Vapor Ablation (BTVA) for Lung Volume Reduction

NCT01041586
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease
Interventions
BTVA System
Device
Lead sponsor
Uptake Medical Corp
Industry
Eligibility
40 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Phoenix, Arizona • Iowa City, Iowa • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2012 · Synced Oct 6, 2026, 10:13 PM EDT
Recruiting Phase 2 Interventional

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT07759245
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Brenipatide, Placebo, Standard of Care
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years to 75 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Newport Beach, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Results available

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

NCT00932646
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BI 1744 (Olodaterol) Low Dose, BI 1744 (Olodaterol) Medium Dose, Placebo, Foradil
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2016 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 1 Interventional

Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01013142
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
MN-221 (Dose Group 1), MN-221 (Dose Group 2), MN-221 (Dose Group 3)
Drug
Lead sponsor
MediciNova
Industry
Eligibility
40 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Fullerton, California • Tamarac, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 6, 2026, 10:13 PM EDT
Completed No phase listed Observational

Dietary Intake in Adults From the GA2LEN Folow-up Survey

NCT03251157
View directory record Official record
Conditions
Asthma, Lung Function Decreased, Food Allergy, Allergic Sensitisation, Allergic Rhinitis, COPD, Atopy
Interventions
Dietary intake of various nutrients, foods and biocompounds
Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
15 Years to 75 Years
Enrollment
3,500 participants
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 6, 2026, 10:13 PM EDT